The Neuropathic Pain Market is projected to reach $15.37 billion by 2033, with a CAGR of 8.29% from 2026 to 2033. The US market is estimated at $2.95 billion in 2025, expected to grow at a CAGR of 8.07%. Anticonvulsants lead the market, while Chemotherapy Induced Neuropathy is the top application. Oral administration dominates, with Retail Pharmacy leading distribution channels. North America dominates the market, while the Asia Pacific region is projected to have the fastest-growing CAGR of 9.66%.

In recent developments, Sun Pharmaceutical launched a generic version of Gabapentin in Canada, expanding their presence in the neuropathic pain market. Biogen partnered with Stoke Therapeutics to develop zorevunersen for Dravet syndrome.

For more information on the Neuropathic Pain Market, visit SNS Insider for a comprehensive report including patient adherence metrics, treatment effectiveness, prescription behavior insights, and market response analysis. Explore related reports on Peripheral Neuropathy, Pain Management, Diabetic Neuropathy, Antidepressants, and Analgesics Markets to stay informed. SNS Insider is a leading market research and consulting agency providing clients with accurate market data and insights to make confident decisions.

Read more at GlobeNewswire: Neuropathic Pain Market Size to Surpass $15.37 Billion by